Company Overview - Stoke Therapeutics is an early-stage biotechnology company focused on designing RNA-based therapeutics for severe genetic diseases, leveraging a proprietary platform [5] - The company has a market capitalization of $1.9 billion and reported a revenue of $184.4 million with a net income of -$6.9 million for the trailing twelve months [4] - The stock price has increased by 340% over the past year, indicating strong market performance [4] Transaction Summary - Arthur Tzianabos, the chair of Stoke Therapeutics, sold 4,355 shares of Common Stock for approximately $174,000 on March 10, 2026 [1][2] - Post-transaction, Tzianabos holds 31,339 shares directly, with a total direct ownership value of about $1.20 million [2] - The transaction was linked to the exercise of 3,955 stock options, suggesting it was a liquidity event related to equity compensation rather than a reduction in long-held equity [6] Clinical Development - Stoke Therapeutics is advancing its pipeline with lead clinical candidates STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy, with STK-002 recently entering a Phase 1 study [7][9] - The company has published data indicating that its lead candidate, zorevunersen, shows lasting reductions in seizures and improvements in cognition and behavior for patients with Dravet syndrome, positioning it as a potential disease-modifying therapy [9] Investor Implications - The recent share sale by Tzianabos reflects compensation structures rather than a change in sentiment, as a significant portion of his holdings remains in stock options [8] - For long-term investors, the focus should be on the execution risks associated with clinical data and regulatory approval, as the current valuation is based on considerable success [10]

Core Insights - Stoke Therapeutics is an early-stage biotechnology company focused on developing RNA-based therapies for severe genetic diseases, particularly rare neurological disorders [1] - The company has a proprietary platform called Targeted Augmentation of Nuclear Gene Output, which it leverages to advance its clinical pipeline and establish partnerships for commercialization [1] - Stoke's lead candidate, zorevunersen, is in late-stage development for Dravet syndrome, and the company has recently initiated a Phase 1 study for STK-002 targeting autosomal dominant optic atrophy [8] Company Developments - Barry Ticho, the chief medical officer, sold 14,311 shares of Common Stock for approximately $457,000, following a significant one-year gain of 300% for the company [2][6] - Ticho's direct ownership decreased by 26.01%, from 55,013 to 40,702 shares, but he retains 83,035 stock options, indicating substantial future potential [3] - The sale was part of a routine trading plan and involved the exercise of options, reflecting a larger-than-typical disposition compared to Ticho's historical trading activity [4][5][7] Market Context - The company's stock has surged approximately 300% over the past year, leading to heightened expectations for future performance [8] - Insider selling after significant stock rallies is common, and the focus for investors will be on upcoming clinical data to assess the company's long-term potential [9]

Core Insights - The investigational medicine zorevunersen shows potential for disease modification in Dravet syndrome, a severe genetic neurodevelopmental disorder, with significant reductions in seizures and improvements in cognition and behavior [1][4][10] Company Overview - Stoke Therapeutics, a biotechnology company focused on RNA medicine, is developing zorevunersen to restore protein expression and treat Dravet syndrome [1][14] - Biogen Inc. collaborates with Stoke Therapeutics to develop and commercialize zorevunersen, retaining exclusive rights in certain regions [10][15] Clinical Study Results - Data from Phase 1/2a studies indicate that zorevunersen led to substantial and durable reductions in seizure frequency, particularly with initial doses of 70 mg [4][11] - Improvements in neurodevelopment, functioning, and quality of life were observed over three years of treatment in open-label extension studies [5][12] Safety Profile - Zorevunersen has been generally well tolerated, with 81 patients evaluated for safety and over 800 doses administered [6][11] - The most common adverse event was elevated cerebrospinal fluid protein levels, with no related clinical manifestations reported [6][12] Future Developments - The ongoing Phase 3 EMPEROR study aims to further evaluate the efficacy and safety of zorevunersen, with results expected in mid-2027 [8][13] - The study will enroll approximately 150 patients and assess the percentage change in major motor seizure frequency as the primary endpoint [13]

Summary of Stoke Therapeutics FY Conference Call Company Overview - **Company**: Stoke Therapeutics (NasdaqGS:STOK) - **Focus**: Development of treatments for Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA) Key Points on Dravet Syndrome - **Market Opportunity**: Approximately 35,000-40,000 patients in the core geographies (U.S., Japan, U.K., EU 4) with about 16,000 in the U.S. and a similar number in the EU 4 [85][86] - **Addressable Patients**: 6,000 patients are immediately addressable upon launch, with 4,000 being pediatric patients aged 18 and younger [85][86] - **FDA Interactions**: Ongoing discussions with the FDA regarding the potential success of the phase 3 study and the importance of the label for pricing and promotion [15][71] - **Clinical Data**: Phase 1, 2 studies show robust seizure reduction and improvements in cognition and behavior, with a focus on longitudinal data over a 5-year period [17][19][20] - **Primary Endpoint**: Seizure reduction at 26 weeks, with secondary endpoints including cognition and behavior assessed at 52 weeks [48][55] - **Vineland Assessment**: Statistical improvements observed in Vineland scores, indicating cognitive and behavioral benefits [23][25] Phase 3 Study (EMPEROR) - **Enrollment Status**: Approximately 160 patients enrolled in the U.S. and Europe, with completion expected in mid-2027 [26][27] - **Study Design**: Includes lumbar puncture sham control patients and additional cohorts for regulatory compliance [27][35] - **Powering of Study**: Designed for a 90% confidence level with a p-value of 0.01 for secondary endpoints, ensuring robust statistical significance [48][52] Pricing and Market Dynamics - **Pricing Strategy**: Aiming for a price reflective of the value provided by the treatment, potentially aligning with other genetically targeted disease-modifying treatments rather than traditional anti-seizure medications [103][105] - **Comparison with SPINRAZA**: Pricing expected to be in line with other ASOs like SPINRAZA, which is priced around $600 per dose [118][105] Autosomal Dominant Optic Atrophy (ADOA) - **Patient Population**: Approximately 13,000 patients in the U.S. and Europe, with a significant risk of legal blindness [127] - **Phase 1 Study**: Ongoing dose escalation study with initial dosing completed, aiming to demonstrate efficacy in improving eyesight [128][129] Additional Insights - **Long-term Development**: The treatment aims to provide more years of neurotypical development for children with Dravet syndrome, addressing both seizure control and cognitive development [20][71] - **Genetic Testing**: Increased access and utilization of genetic testing are expected to enhance patient identification, particularly in adults who may have been misdiagnosed [88][90] Conclusion - Stoke Therapeutics is positioned to address significant unmet needs in the treatment of Dravet syndrome and ADOA, with ongoing clinical studies and strategic planning for market entry and pricing. The company emphasizes the importance of robust clinical data to support its treatment's efficacy and market potential.

Company Overview - Stoke Therapeutics is a biotechnology company focused on restoring protein expression through RNA medicine, with its lead investigational medicine, zorevunersen, aimed at treating Dravet syndrome, a severe neurodevelopmental disorder characterized by recurrent seizures and cognitive impairments [3][9] - The company was founded in 2015 and has advanced zorevunersen from early clinical testing to late-stage development, preparing for commercialization in the United States [4][9] New Headquarters - Stoke Therapeutics has secured a long-term lease for a new 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, Massachusetts, which is one of the largest leases in the Greater Boston life sciences sector over the past year [1][2] - The relocation is set to occur when the current lease in Bedford, Massachusetts ends in late 2026 [1] Growth and Research Expansion - The new headquarters will support Stoke's growth trajectory as it prepares to commercialize zorevunersen and expand research efforts for additional medicines targeting severe diseases [5] - The Waltham area is recognized as a resilient hub for life sciences, providing operational efficiency and access to top talent, which aligns with Stoke's strategic goals [5] Infrastructure and Sustainability - The new property is LEED Gold and WiredScore Platinum certified, emphasizing sustainability and connectivity, with modern infrastructure designed for lab-ready use [5] Market Context - Despite a moderation in the national life sciences market, the Greater Boston area, particularly Waltham and the Route 128 corridor, continues to demonstrate strength and resilience in supporting the biotech industry [5]

Summary of Stoke Therapeutics FY Conference Call Company Overview - **Company**: Stoke Therapeutics (NasdaqGS:STOK) - **CEO**: Ian Smith, in role since March 2025 - **Focus**: Upregulating protein expression for haplo-insufficient diseases, primarily targeting genetic conditions like Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA) [2][3] Key Developments - **Lead Medicine**: Zorevunersen, targeting Dravet syndrome by upregulating the SCN1A gene to increase NaV1.1 expression, aiming to reduce seizures and improve neurodevelopment [3][4] - **Clinical Trials**: - Currently in Phase 3 for Dravet syndrome with a target enrollment of 150 patients, approximately 60 patients have been randomized, and another 60 are in the screening phase [5][6] - Enrollment expected to complete by Q2 2026, with potential NDA submission in 2027 or early 2028 [6][20] - **Long-term Data**: Patients have been followed for up to four years, showing durability in seizure reduction (up to 85%) and improvements in neurocognition [7][10][18] Financial Position - **Funding**: Approximately $400 million available, sufficient to fund operations through 2028 [8][9] - **Collaboration**: Partnership with Biogen, which licensed commercial rights to zorevunersen and funds 30% of R&D development [21][22] Market Opportunity - **Patient Population**: Estimated 40,000 patients with Dravet syndrome across key geographies (15-20,000 in the U.S. and Europe) [20][21] - **Commercial Potential**: Anticipated robust demand for a disease-modifying treatment, with market research indicating high clinician willingness to prescribe [41][42] Regulatory Pathway - **Breakthrough Designation**: Zorevunersen has received this designation, allowing for expedited development discussions with the FDA [27][28] - **FDA Interaction**: Productive discussions with the FDA regarding the potential for filing based on Phase 1, 2, and OLE data, although the timeline for filing may not be significantly shortened [28][30] Pipeline and Future Plans - **Next Steps**: - Completion of Phase 3 enrollment and subsequent NDA filing [24][25] - Initiation of clinical trials for ADOA (STK-002) and SYNGAP1, with expectations for early efficacy results by the end of 2026 [50][51] - **Regulatory Strategy**: Focus on demonstrating improvement in vision for ADOA, which could shorten clinical study durations [52][53] Additional Insights - **Data Integrity**: Emphasis on the importance of long-term data and observed outcomes in regulatory discussions to support claims of disease modification [45][46] - **Market Positioning**: Differentiation from existing seizure medications by positioning zorevunersen as a true disease-modifying treatment [48][49] This summary encapsulates the critical points discussed during the Stoke Therapeutics FY Conference Call, highlighting the company's strategic focus, clinical advancements, financial health, and regulatory strategies.

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is advancing zorevunersen as a potential disease-modifying therapy for Dravet Syndrome[9] - Phase 3 study (EMPEROR) enrollment is expected to complete in Q2 2026 with data readout in mid-2027 to support NDA[12, 38] - Approximately 330 patients have been identified globally for the EMPEROR study, with ~60 in screening and ~60 randomized[12, 39] - Data from ongoing OLE studies show continuing improvements in cognition and behavior over 36 months[24] - Zorevunersen demonstrated significant reduction in major motor seizure frequency at 6 months compared to natural history data, with an 8248% reduction compared to a 2043% reduction in the natural history group (P=00181)[26] - In OLE studies, 86% of patients experienced CSF protein elevation, classified as a TEAE in 45%[31] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - A Phase 1 study of STK-002 for ADOA has been initiated in the UK and Europe[11] Financial Status and Collaboration - Stoke Therapeutics had approximately $3917 million in cash, cash equivalents, and marketable securities as of December 31, 2025, with funding anticipated into 2028[12] - A strategic collaboration with Biogen exists for the development and commercialization of zorevunersen, with Biogen holding exclusive commercialization rights outside of the US, Canada, and Mexico[48] - The Biogen collaboration includes $165 million upfront, shared development costs, and potential milestone payments of $385 million[49] Market Opportunity - There are approximately 38,000 patients with Dravet syndrome across 7 major markets[40, 44]

Core Viewpoint - U.S. stock futures are lower, with significant declines in several companies' shares during pre-market trading, particularly Exelixis Inc, which reported preliminary financial results for fiscal year 2025 [1]. Group 1: Exelixis Inc - Exelixis reported preliminary US net product revenue of $2.123 billion for fiscal year 2025 [1]. - The company projects net product revenue for 2026 to be between $2.325 billion and $2.425 billion [1]. - Exelixis shares fell 4.6% to $42.01 in pre-market trading following the announcement [1]. Group 2: Other Companies - Synchrony Financial shares dipped 9.5% to $78.61 in pre-market trading [3]. - Stoke Therapeutics Inc declined 8.7% to $30.00, announcing updates on enrollment timelines and Phase 3 data for zorevunersen [3]. - Capital One Financial Corp fell 8.4% to $228.35 in pre-market trading [3]. - Bread Financial Holdings Inc tumbled 8.3% to $73.72 [3]. - Himalaya Shipping Ltd dipped 5.7% to $8.72 [3]. - Mesoblast Ltd fell 5.1% to $19.90, despite a previous gain after reporting increased sales [3]. - American Express Co declined 5% to $357.00 [3]. - Lumentum Holdings Inc fell 4.7% to $335.00 [3]. - WPP PLC declined 4.5% to $22.63 [3]. - Citigroup Inc fell 4% to $116.50, with earnings results expected on January 14 [3].

Core Viewpoint - Stoke Therapeutics, Inc. is advancing its investigational medicine zorevunersen in collaboration with Biogen, targeting Dravet syndrome as a potential first-in-class disease-modifying treatment [1] Group 1: Company Overview - Stoke Therapeutics is focused on restoring protein expression through RNA medicine [1] - The company is developing zorevunersen as its lead investigational medicine [1] Group 2: Development Updates - The company announced accelerated timelines for the completion of enrollment in the clinical trial [1] - A Phase 3 data readout from the EMPEROR study is expected soon [1]

Core Insights - Oligonucleotide therapies are emerging as a significant breakthrough in the treatment of rare diseases, with over a dozen therapies approved globally and hundreds in clinical research, promising to benefit more patients in the future [1][14][15] Industry Developments - The global landscape has seen more than ten oligonucleotide therapies approved for rare diseases, providing new treatment options for conditions such as Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), and Hemophilia [1][14] - There are currently over a hundred oligonucleotide therapies in clinical development targeting various rare diseases, including siRNA and antisense oligonucleotide (ASO) therapies [2][14] Recent Approvals and Innovations - In August, Ionis Pharmaceuticals received FDA approval for the LICA drug Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older, marking it as the first RNA-targeted drug for HAE [4][18] - Ionis Pharmaceuticals and Sobi announced the approval of ASO drug Tryngolza (olezarsen) in the EU for treating genetically confirmed familial chylomicronemia syndrome (FCS) [4][19] - Alnylam Pharmaceuticals' siRNA therapy Amvuttra (vutrisiran) was approved by the FDA in March for treating patients with transthyretin amyloidosis with cardiomyopathy [5][19] Clinical Trial Progress - NS Pharma reported positive results from the long-term extension study of ASO therapy brogidirsen for DMD, showing effective exon 44 skipping and stable maintenance of motor function in patients [7][21] - RIBOMIC's umedaptanib pegol showed promising results in a Phase 2 trial for achondroplasia in children, with many patients experiencing improved height growth rates [7][21] - Ionis Pharmaceuticals' ASO therapy zilganersen demonstrated significant results in stabilizing walking speed in Alexander disease patients, with plans for a new drug application to the FDA in 2026 [8][22] WuXi TIDES Platform - WuXi TIDES has established an integrated solution for oligonucleotide and peptide therapies, covering custom synthesis, conjugation, process development, and CMC, facilitating the transition of innovative projects into clinical stages [1][11][26] - The platform offers comprehensive CRDMO services from drug discovery to commercial production, supporting high-throughput synthesis and custom synthesis for various oligonucleotides [11][26][27] Future Outlook - The company aims to continue leveraging its integrated CRDMO model to empower the development of various new drugs, including oligonucleotide therapies, to bring more effective treatments to patients [12][27]